22MA088 T cell engineering: Bcl-XL Variants for Enhancing Cellular Immunotherapy Function
Lack of persistence and sensitivity to apoptosis and activation induced cell death are key contributors to cellular immunotherapy failure. The protein Bcl-Xl functions as an anti-apoptotic protein that resides in mitochondria. Moffitt researchers found that certain amino acid utations help Bcl-Xl maintain this crucial antiapoptotic function. A mutated Bcl-Xl variant was created, and was found to produce a more potent and durable immune response by reducing exhaustion, maintaining function, and increasing the viability of T-cells. Our novel egradation-resistant Bcl-Xl variant increased efficacy of cellular immunotherapies.
PUBLICATION/PATENT
Provisional Patent filed for Drs. Locke and Atkins
CONTACT
InnovationMarketing@Moffitt.org
(813) 745-6828